Daniel Heng, MD, MPH, FRCPC, discusses first-line treatment selection and the role of second-line belzutifan plus lenvatinib in advanced RCC.
Daniel Heng, MD, MPH, FRCPC
Advertisement
Articles by Daniel Heng, MD, MPH, FRCPC
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Subcutaneous Toripalimab Plus Disitamab Vedotin sNDA Is Accepted in China for HER2-Expressing Urothelial Cancer
2
Broadening HER2-Mutated NSCLC Data Support First-Line Zongertinib Followed by T-DXd
3
Combining 2 VEGF-Blocking Targeted Therapies Significantly Boosted Survival in Kidney Cancer Study
4
Thorough Treatment Adherence and Selection Anchor Proper TKI Utilization in CML
5